US20120196370A1
(en)
*
|
2010-12-03 |
2012-08-02 |
Fyodor Urnov |
Methods and compositions for targeted genomic deletion
|
EP2206723A1
(en)
|
2009-01-12 |
2010-07-14 |
Bonas, Ulla |
Modular DNA-binding domains
|
US20110239315A1
(en)
|
2009-01-12 |
2011-09-29 |
Ulla Bonas |
Modular dna-binding domains and methods of use
|
US8399643B2
(en)
|
2009-02-26 |
2013-03-19 |
Transposagen Biopharmaceuticals, Inc. |
Nucleic acids encoding hyperactive PiggyBac transposases
|
EP2510096B2
(en)
|
2009-12-10 |
2018-02-07 |
Regents of the University of Minnesota |
Tal effector-mediated dna modification
|
BR112012020257A8
(pt)
*
|
2010-02-11 |
2018-02-14 |
Recombinetics Inc |
métodos e aparelhos para produzir artiodátilos transgênicos
|
CA2798988C
(en)
|
2010-05-17 |
2020-03-10 |
Sangamo Biosciences, Inc. |
Tal-effector (tale) dna-binding polypeptides and uses thereof
|
EP2392208B1
(en)
*
|
2010-06-07 |
2016-05-04 |
Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Fusion proteins comprising a DNA-binding domain of a Tal effector protein and a non-specific cleavage domain of a restriction nuclease and their use
|
US9528124B2
(en)
|
2013-08-27 |
2016-12-27 |
Recombinetics, Inc. |
Efficient non-meiotic allele introgression
|
US10920242B2
(en)
|
2011-02-25 |
2021-02-16 |
Recombinetics, Inc. |
Non-meiotic allele introgression
|
US9161995B2
(en)
|
2011-07-25 |
2015-10-20 |
Sangamo Biosciences, Inc. |
Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
|
EP3498833B1
(en)
|
2011-09-21 |
2023-08-16 |
Sangamo Therapeutics, Inc. |
Methods and compositions for regulation of transgene expression
|
US9222105B2
(en)
|
2011-10-27 |
2015-12-29 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of the HPRT locus
|
GB201122458D0
(en)
|
2011-12-30 |
2012-02-08 |
Univ Wageningen |
Modified cascade ribonucleoproteins and uses thereof
|
EP3839050A3
(en)
*
|
2012-04-18 |
2021-09-29 |
The Board of Trustees of the Leland Stanford Junior University |
Non-disruptive gene targeting
|
EP2847335B1
(en)
*
|
2012-04-25 |
2018-06-27 |
Regeneron Pharmaceuticals, Inc. |
Nuclease-mediated targeting with large targeting vectors
|
US9523098B2
(en)
|
2012-05-02 |
2016-12-20 |
Dow Agrosciences Llc |
Targeted modification of malate dehydrogenase
|
WO2013169802A1
(en)
|
2012-05-07 |
2013-11-14 |
Sangamo Biosciences, Inc. |
Methods and compositions for nuclease-mediated targeted integration of transgenes
|
PE20150336A1
(es)
|
2012-05-25 |
2015-03-25 |
Univ California |
Metodos y composiciones para la modificacion de adn objetivo dirigida por arn y para la modulacion de la transcripcion dirigida por arn
|
WO2013182910A2
(en)
*
|
2012-06-05 |
2013-12-12 |
Cellectis |
New transcription activator-like effector (tale) fusion protein
|
US20150225734A1
(en)
|
2012-06-19 |
2015-08-13 |
Regents Of The University Of Minnesota |
Gene targeting in plants using dna viruses
|
WO2013191769A1
(en)
*
|
2012-06-22 |
2013-12-27 |
Mayo Foundation For Medical Education And Research |
Genome editing
|
AU2013289206B2
(en)
|
2012-07-11 |
2018-08-09 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of lysosomal storage diseases
|
WO2014011901A2
(en)
|
2012-07-11 |
2014-01-16 |
Sangamo Biosciences, Inc. |
Methods and compositions for delivery of biologics
|
US10648001B2
(en)
|
2012-07-11 |
2020-05-12 |
Sangamo Therapeutics, Inc. |
Method of treating mucopolysaccharidosis type I or II
|
EP3808844A1
(en)
*
|
2012-07-25 |
2021-04-21 |
The Broad Institute, Inc. |
Inducible dna binding proteins and genome perturbation tools and applications thereof
|
US10058078B2
(en)
|
2012-07-31 |
2018-08-28 |
Recombinetics, Inc. |
Production of FMDV-resistant livestock by allele substitution
|
WO2014033644A2
(en)
|
2012-08-28 |
2014-03-06 |
Novartis Ag |
Methods of nuclease-based genetic engineering
|
MX367081B
(es)
|
2012-08-29 |
2019-08-05 |
Sangamo Biosciences Inc |
Modificación genética mediada por nucleasas para usarse en el tratamiento de una condición genética.
|
CN105264067B
(zh)
|
2012-09-07 |
2020-11-10 |
美国陶氏益农公司 |
Fad3性能基因座及相应的能够诱导靶向断裂的靶位点特异性结合蛋白
|
UA118090C2
(uk)
|
2012-09-07 |
2018-11-26 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Спосіб інтегрування послідовності нуклеїнової кислоти, що представляє інтерес, у ген fad2 у клітині сої та специфічний для локусу fad2 білок, що зв'язується, здатний індукувати спрямований розрив
|
GB201216564D0
(en)
|
2012-09-17 |
2012-10-31 |
Univ Edinburgh |
Genetically edited animal
|
HUE050797T2
(hu)
|
2012-10-10 |
2021-01-28 |
Sangamo Therapeutics Inc |
T-sejt módosító vegyületek és alkalmazásaik
|
CN104968193B
(zh)
|
2012-11-01 |
2021-02-09 |
塞尔克蒂斯股份有限公司 |
用于生成治疗性蛋白质的植物
|
EP2929017A4
(en)
*
|
2012-12-05 |
2016-09-28 |
Sangamo Biosciences Inc |
METHODS AND COMPOSITIONS FOR REGULATION OF METABOLIC DISORDERS
|
KR101844123B1
(ko)
|
2012-12-06 |
2018-04-02 |
시그마-알드리치 컴퍼니., 엘엘씨 |
Crispr-기초된 유전체 변형과 조절
|
EP3434776A1
(en)
|
2012-12-12 |
2019-01-30 |
The Broad Institute, Inc. |
Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
MX2015007550A
(es)
|
2012-12-12 |
2017-02-02 |
Broad Inst Inc |
Suministro, modificación y optimización de sistemas, métodos y composiciones para la manipulación de secuencias y aplicaciones terapéuticas.
|
WO2014096972A2
(en)
|
2012-12-21 |
2014-06-26 |
Cellectis |
Potatoes with reduced cold-induced sweetening
|
WO2014102688A1
(en)
*
|
2012-12-27 |
2014-07-03 |
Cellectis |
New design matrix for improvement of homology-directed gene targeting
|
WO2014130955A1
(en)
|
2013-02-25 |
2014-08-28 |
Sangamo Biosciences, Inc. |
Methods and compositions for enhancing nuclease-mediated gene disruption
|
ES2901396T3
(es)
|
2013-03-14 |
2022-03-22 |
Caribou Biosciences Inc |
Composiciones y métodos de ácidos nucleicos dirigidos a ácido nucleico
|
PT2971039T
(pt)
|
2013-03-14 |
2020-05-06 |
Immusoft Corp |
Métodos para diferenciação e transdução in vitro de células b de memória com vetores virais pseudotipados vsv-g
|
US9957515B2
(en)
|
2013-03-15 |
2018-05-01 |
Cibus Us Llc |
Methods and compositions for targeted gene modification
|
US10113162B2
(en)
|
2013-03-15 |
2018-10-30 |
Cellectis |
Modifying soybean oil composition through targeted knockout of the FAD2-1A/1B genes
|
JP6346266B2
(ja)
|
2013-03-21 |
2018-06-20 |
サンガモ セラピューティクス, インコーポレイテッド |
操作されたジンクフィンガータンパク質ヌクレアーゼを使用するt細胞受容体遺伝子の標的化された破壊
|
KR102192599B1
(ko)
|
2013-04-05 |
2020-12-18 |
다우 아그로사이언시즈 엘엘씨 |
식물의 게놈 내의 외인성 서열의 통합을 위한 방법 및 조성물
|
PT3456831T
(pt)
|
2013-04-16 |
2021-09-10 |
Regeneron Pharma |
Modificação alvejada do genoma de rato
|
EP2994531B1
(en)
|
2013-05-10 |
2018-03-28 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
CN116083487A
(zh)
|
2013-05-15 |
2023-05-09 |
桑格摩生物治疗股份有限公司 |
用于治疗遗传病状的方法和组合物
|
US10413509B2
(en)
*
|
2013-05-30 |
2019-09-17 |
Nanobiotix |
Pharmaceutical composition, preparation and uses thereof
|
KR20160034901A
(ko)
*
|
2013-06-17 |
2016-03-30 |
더 브로드 인스티튜트, 인코퍼레이티드 |
서열 조작에 최적화된 crispr-cas 이중 닉카아제 시스템, 방법 및 조성물
|
EP3011033B1
(en)
|
2013-06-17 |
2020-02-19 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
DK3011031T3
(da)
|
2013-06-17 |
2020-12-21 |
Broad Inst Inc |
Fremføring og anvendelse af crispr-cas-systemerne, vektorer og sammensætninger til levermålretning og -terapi
|
SG11201510286QA
(en)
|
2013-06-17 |
2016-01-28 |
Broad Inst Inc |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components
|
ES2777217T3
(es)
*
|
2013-06-17 |
2020-08-04 |
Broad Inst Inc |
Suministro, modificación y optimización de sistemas de guía en tándem, métodos y composiciones para la manipulación de secuencias
|
WO2015017866A1
(en)
|
2013-08-02 |
2015-02-05 |
Enevolv, Inc. |
Processes and host cells for genome, pathway, and biomolecular engineering
|
EP3039136B8
(en)
|
2013-08-28 |
2020-12-16 |
Sangamo Therapeutics, Inc. |
Compositions for linking dna-binding domains and cleavage domains
|
WO2015057976A1
(en)
|
2013-10-17 |
2015-04-23 |
Sangamo Biosciences, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
|
AU2014337248B2
(en)
|
2013-10-17 |
2020-09-24 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
ES2962492T3
(es)
|
2013-10-25 |
2024-03-19 |
Livestock Improvement Corporation Ltd |
Marcadores genéticos y usos de los mismos
|
BR102014027466B1
(pt)
|
2013-11-04 |
2022-09-27 |
Dow Agrosciences Llc |
Molécula de ácido nucleico recombinante, método para produzir uma célula vegetal transgênica e usos de uma planta de soja, parte de planta de soja ou célula de planta de soja transgênica
|
US10233465B2
(en)
|
2013-11-04 |
2019-03-19 |
Dow Agrosciences Llc |
Optimal soybean loci
|
AU2014341927B2
(en)
|
2013-11-04 |
2017-12-14 |
Corteva Agriscience Llc |
Optimal maize loci
|
MX364662B
(es)
*
|
2013-11-04 |
2019-05-03 |
Dow Agrosciences Llc |
Óptimos loci de maíz.
|
PT3068881T
(pt)
|
2013-11-13 |
2019-05-31 |
Childrens Medical Center |
Regulação da expressão de genes mediada por nucleases
|
WO2015073867A1
(en)
*
|
2013-11-15 |
2015-05-21 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Engineering neural stem cells using homologous recombination
|
JP6535684B2
(ja)
|
2013-12-09 |
2019-06-26 |
サンガモ セラピューティクス, インコーポレイテッド |
ゲノム操作のための方法および組成物
|
CN105980568B
(zh)
|
2013-12-11 |
2019-12-03 |
瑞泽恩制药公司 |
用于靶向修饰基因组的方法和组合物
|
DK3079725T3
(da)
|
2013-12-12 |
2020-01-20 |
Broad Inst Inc |
Administration, brug og terapeutiske anvendelser af crispr-cas-systemerne og sammensætninger til genomredigering
|
WO2015089364A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Crystal structure of a crispr-cas system, and uses thereof
|
WO2015089486A2
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
|
JP6625055B2
(ja)
|
2013-12-12 |
2020-01-08 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
組成物、及びヌクレオチドリピート障害におけるcrispr−cas系の使用方法
|
US10774338B2
(en)
|
2014-01-16 |
2020-09-15 |
The Regents Of The University Of California |
Generation of heritable chimeric plant traits
|
US10233456B2
(en)
|
2014-01-30 |
2019-03-19 |
The Board Of Trustees Of The University Of Arkansas |
Method, vectors, cells, seeds and kits for stacking genes into a single genomic site
|
RS60514B1
(sr)
|
2014-02-03 |
2020-08-31 |
Sangamo Therapeutics Inc |
Postupci i sastavi za tretman beta talasemije
|
US10370680B2
(en)
|
2014-02-24 |
2019-08-06 |
Sangamo Therapeutics, Inc. |
Method of treating factor IX deficiency using nuclease-mediated targeted integration
|
UA124375C2
(uk)
*
|
2014-03-14 |
2021-09-08 |
Кібус Юс Ллс |
Спосіб здійснення спрямованої генетичної зміни днк в клітині рослини з використанням нуклеази crispr і модифікованого gron
|
CN106459894B
(zh)
|
2014-03-18 |
2020-02-18 |
桑格摩生物科学股份有限公司 |
用于调控锌指蛋白表达的方法和组合物
|
WO2015164748A1
(en)
|
2014-04-24 |
2015-10-29 |
Sangamo Biosciences, Inc. |
Engineered transcription activator like effector (tale) proteins
|
JP2017517250A
(ja)
*
|
2014-04-28 |
2017-06-29 |
シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニーSigma−Aldrich Co., LLC |
標的エンドヌクレアーゼを用いる哺乳類ゲノムのエピジェネティック修飾
|
CN106535630B
(zh)
*
|
2014-04-28 |
2020-04-24 |
重组股份有限公司 |
多重基因编辑
|
GB201407852D0
(en)
|
2014-05-02 |
2014-06-18 |
Iontas Ltd |
Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
|
WO2015175642A2
(en)
|
2014-05-13 |
2015-11-19 |
Sangamo Biosciences, Inc. |
Methods and compositions for prevention or treatment of a disease
|
US9970001B2
(en)
|
2014-06-05 |
2018-05-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for nuclease design
|
LT3152312T
(lt)
|
2014-06-06 |
2020-04-27 |
Regeneron Pharmaceuticals, Inc. |
Tikslinio lokuso modifikavimo būdai ir kompozicijos
|
CA2952906A1
(en)
|
2014-06-20 |
2015-12-23 |
Cellectis |
Potatoes with reduced granule-bound starch synthase
|
CN106604994B
(zh)
*
|
2014-06-23 |
2021-12-14 |
通用医疗公司 |
通过测序评估的DSBs的全基因组无偏鉴定(GUIDE-Seq)
|
RU2771532C2
(ru)
|
2014-06-26 |
2022-05-05 |
Регенерон Фармасьютикалз, Инк. |
Способы и композиции для нацеленных генетических модификаций и способы их применения
|
WO2016011029A2
(en)
|
2014-07-14 |
2016-01-21 |
Washington State University |
Nanos knock-out that ablates germline cells
|
WO2016014794A1
(en)
|
2014-07-25 |
2016-01-28 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
|
US9757420B2
(en)
|
2014-07-25 |
2017-09-12 |
Sangamo Therapeutics, Inc. |
Gene editing for HIV gene therapy
|
WO2016019144A2
(en)
|
2014-07-30 |
2016-02-04 |
Sangamo Biosciences, Inc. |
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
|
CN107073091A
(zh)
|
2014-09-07 |
2017-08-18 |
西莱克塔生物科技公司 |
用于减弱外显子跳读抗病毒转移载体免疫应答的方法和组合物
|
SG11201702134RA
(en)
|
2014-09-16 |
2017-04-27 |
Sangamo Therapeutics Inc |
Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells
|
CA2963820A1
(en)
|
2014-11-07 |
2016-05-12 |
Editas Medicine, Inc. |
Methods for improving crispr/cas-mediated genome-editing
|
US20170369848A1
(en)
*
|
2014-11-11 |
2017-12-28 |
Q Therapeutics, Inc. |
Engineering mesenchymal stem cells using homologous recombination
|
KR20230070319A
(ko)
|
2014-11-21 |
2023-05-22 |
리제너론 파마슈티칼스 인코포레이티드 |
쌍 형성된 가이드 rna를 사용하는 표적화된 유전자 변형을 위한 방법 및 조성물
|
WO2016094867A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Protected guide rnas (pgrnas)
|
US10889834B2
(en)
|
2014-12-15 |
2021-01-12 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing targeted transgene integration
|
BR112017013104A2
(pt)
|
2014-12-19 |
2018-05-15 |
Regeneron Pharma |
métodos para modificar um locus genômico alvo em uma célula, para intensificar a recombinação homóloga em um locus genômico alvo em uma célula e para produzir uma geração f0 de um animal não humano.
|
EP3247366A4
(en)
|
2015-01-21 |
2018-10-31 |
Sangamo Therapeutics, Inc. |
Methods and compositions for identification of highly specific nucleases
|
US10179918B2
(en)
|
2015-05-07 |
2019-01-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for increasing transgene activity
|
WO2016183298A2
(en)
|
2015-05-12 |
2016-11-17 |
Sangamo Biosciences, Inc. |
Nuclease-mediated regulation of gene expression
|
WO2016205613A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Crispr enzyme mutations reducing off-target effects
|
WO2016205759A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
|
US9957501B2
(en)
|
2015-06-18 |
2018-05-01 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
US10450585B2
(en)
|
2015-07-13 |
2019-10-22 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
US10091975B2
(en)
|
2015-08-06 |
2018-10-09 |
The Curators Of The University Of Missouri |
Pathogen-resistant animals having modified CD163 genes
|
JP2018530536A
(ja)
|
2015-09-11 |
2018-10-18 |
ザ ジェネラル ホスピタル コーポレイション |
ヌクレアーゼDSBの完全照合およびシーケンシング(FIND−seq)
|
US10837024B2
(en)
|
2015-09-17 |
2020-11-17 |
Cellectis |
Modifying messenger RNA stability in plant transformations
|
EA037993B1
(ru)
|
2015-09-23 |
2021-06-21 |
Сангамо Терапьютикс, Инк. |
Репрессоры htt и их применение
|
EP3786294A1
(en)
|
2015-09-24 |
2021-03-03 |
Editas Medicine, Inc. |
Use of exonucleases to improve crispr/cas-mediated genome editing
|
US9850484B2
(en)
|
2015-09-30 |
2017-12-26 |
The General Hospital Corporation |
Comprehensive in vitro reporting of cleavage events by sequencing (Circle-seq)
|
CA3002524A1
(en)
|
2015-10-28 |
2017-05-04 |
Sangamo Therapeutics, Inc. |
Liver-specific constructs, factor viii expression cassettes and methods of use thereof
|
EP3380622A4
(en)
|
2015-11-23 |
2019-08-07 |
Sangamo Therapeutics, Inc. |
METHODS AND COMPOSITIONS FOR MODIFYING IMMUNITY
|
WO2017106528A2
(en)
|
2015-12-18 |
2017-06-22 |
Sangamo Biosciences, Inc. |
Targeted disruption of the t cell receptor
|
IL297018A
(en)
|
2015-12-18 |
2022-12-01 |
Sangamo Therapeutics Inc |
Directed cleavage of cell mhc receptor
|
US11427837B2
(en)
|
2016-01-12 |
2022-08-30 |
The Regents Of The University Of California |
Compositions and methods for enhanced genome editing
|
ES2895430T3
(es)
|
2016-01-15 |
2022-02-21 |
Univ Minnesota |
Métodos y composiciones para el tratamiento de enfermedad neurológica
|
KR20180101442A
(ko)
|
2016-02-02 |
2018-09-12 |
상가모 테라퓨틱스, 인코포레이티드 |
Dna-결합 도메인 및 절단 도메인을 연결시키기 위한 조성물
|
EP3410843A1
(en)
|
2016-02-02 |
2018-12-12 |
Cellectis |
Modifying soybean oil composition through targeted knockout of the fad3a/b/c genes
|
US11597924B2
(en)
|
2016-03-25 |
2023-03-07 |
Editas Medicine, Inc. |
Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
|
EP3443086B1
(en)
|
2016-04-13 |
2021-11-24 |
Editas Medicine, Inc. |
Cas9 fusion molecules, gene editing systems, and methods of use thereof
|
WO2017205650A1
(en)
*
|
2016-05-27 |
2017-11-30 |
Life Technologies Corporation |
Compositions and methods for enhancing homologous recombination
|
AU2017274145B2
(en)
|
2016-06-02 |
2020-07-23 |
Sigma-Aldrich Co Llc |
Using programmable DNA binding proteins to enhance targeted genome modification
|
EP3497115A4
(en)
|
2016-08-15 |
2020-07-29 |
enEvolv, Inc. |
MOLECULE SENSOR SYSTEMS
|
SG11201901364VA
(en)
|
2016-08-24 |
2019-03-28 |
Sangamo Therapeutics Inc |
Engineered target specific nucleases
|
SG10201913315SA
(en)
|
2016-08-24 |
2020-02-27 |
Sangamo Therapeutics Inc |
Regulation of gene expression using engineered nucleases
|
AU2017324462B2
(en)
|
2016-09-07 |
2024-03-21 |
Sangamo Therapeutics, Inc. |
Modulation of liver genes
|
AU2017336094A1
(en)
|
2016-09-29 |
2019-04-18 |
Immunitybio, Inc. |
HLA class I-deficient NK-92 cells with decreased immunogenicity
|
CN110139873A
(zh)
|
2016-10-03 |
2019-08-16 |
朱诺治疗学股份有限公司 |
Hpv特异性结合分子
|
EP3528852A4
(en)
|
2016-10-20 |
2020-06-03 |
Sangamo Therapeutics, Inc. |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF FABRY'S DISEASE
|
WO2018081775A1
(en)
|
2016-10-31 |
2018-05-03 |
Sangamo Therapeutics, Inc. |
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
|
CA3042857A1
(en)
|
2016-11-16 |
2018-05-24 |
Cellectis |
Methods for altering amino acid content in plants through frameshift mutations
|
CN110249051A
(zh)
|
2016-12-08 |
2019-09-17 |
凯斯西储大学 |
增强功能性髓鞘产生的方法和组合物
|
WO2018129346A1
(en)
|
2017-01-06 |
2018-07-12 |
Nantkwest, Inc. |
Genetically modified nk-92 cells with decreased cd96/tigit expression
|
US10143187B2
(en)
|
2017-02-17 |
2018-12-04 |
Denali Therapeutics Inc. |
Transferrin receptor transgenic models
|
US10457717B2
(en)
|
2017-02-17 |
2019-10-29 |
Denali Therapeutics Inc. |
Engineered polypeptides
|
SI3583120T1
(sl)
|
2017-02-17 |
2023-02-28 |
Denali Therapeutics Inc. |
Inženirani polipeptidi, ki vezujejo transferinske receptorje
|
JP2020510418A
(ja)
|
2017-02-17 |
2020-04-09 |
デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. |
トランスフェリン受容体トランスジェニックモデル
|
WO2018198049A1
(en)
|
2017-04-25 |
2018-11-01 |
Cellectis |
Alfalfa with reduced lignin composition
|
AU2018256877B2
(en)
|
2017-04-28 |
2022-06-02 |
Acuitas Therapeutics, Inc. |
Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
CA3059793A1
(en)
|
2017-05-03 |
2018-11-08 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (cftr) gene
|
US11512287B2
(en)
|
2017-06-16 |
2022-11-29 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell and/or HLA receptors
|
EP3652312A1
(en)
|
2017-07-14 |
2020-05-20 |
Editas Medicine, Inc. |
Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
|
WO2019040650A1
(en)
|
2017-08-23 |
2019-02-28 |
The General Hospital Corporation |
GENETICALLY MODIFIED CRISPR-CAS9 NUCLEASES HAVING MODIFIED PAM SPECIFICITY
|
WO2019070541A1
(en)
|
2017-10-03 |
2019-04-11 |
Juno Therapeutics, Inc. |
HPV-SPECIFIC BINDING MOLECULES
|
US11725228B2
(en)
|
2017-10-11 |
2023-08-15 |
The General Hospital Corporation |
Methods for detecting site-specific and spurious genomic deamination induced by base editing technologies
|
JP7427584B2
(ja)
|
2017-10-13 |
2024-02-05 |
セレクタ バイオサイエンシーズ インコーポレーテッド |
抗ウイルス導入ベクターigm応答を減弱化するための方法および組成物
|
US11851679B2
(en)
|
2017-11-01 |
2023-12-26 |
Juno Therapeutics, Inc. |
Method of assessing activity of recombinant antigen receptors
|
SG11202004003YA
(en)
|
2017-11-09 |
2020-05-28 |
Sangamo Therapeutics Inc |
Genetic modification of cytokine inducible sh2-containing protein (cish) gene
|
EP3728598A1
(en)
|
2017-12-21 |
2020-10-28 |
Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
Nucleic acid sequence replacement by nhej
|
JP7275152B2
(ja)
|
2018-02-08 |
2023-05-17 |
サンガモ セラピューティクス, インコーポレイテッド |
操作された標的特異的なヌクレアーゼ
|
JP2021515037A
(ja)
|
2018-02-26 |
2021-06-17 |
アントルクス,インコーポレーテッド |
寛容原性リポソーム及びその使用方法
|
EP3765601A1
(en)
|
2018-03-16 |
2021-01-20 |
Immusoft Corporation |
B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strength
|
MX2020010460A
(es)
|
2018-04-05 |
2021-01-29 |
Juno Therapeutics Inc |
Receptores de células t, y células diseñadas que expresan los mismos.
|
JP2021520211A
(ja)
|
2018-04-05 |
2021-08-19 |
ジュノー セラピューティクス インコーポレイテッド |
組換え受容体を発現するt細胞、関連ポリヌクレオチド、および方法
|
CA3094468A1
(en)
|
2018-04-05 |
2019-10-10 |
Juno Therapeutics, Inc. |
Methods of producing cells expressing a recombinant receptor and related compositions
|
AU2019256287A1
(en)
|
2018-04-17 |
2020-11-12 |
The General Hospital Corporation |
Sensitive in vitro assays for substrate preferences and sites of nucleic acid binding, modifying, and cleaving agents
|
US11421007B2
(en)
|
2018-04-18 |
2022-08-23 |
Sangamo Therapeutics, Inc. |
Zinc finger protein compositions for modulation of huntingtin (Htt)
|
US11690921B2
(en)
|
2018-05-18 |
2023-07-04 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
IL280951B1
(en)
|
2018-08-23 |
2024-04-01 |
Sangamo Therapeutics Inc |
Engineered target-specific base editors
|
WO2020061161A1
(en)
|
2018-09-18 |
2020-03-26 |
Sangamo Therapeutics, Inc. |
Programmed cell death 1 (pd1) specific nucleases
|
CN109161587A
(zh)
*
|
2018-09-26 |
2019-01-08 |
上海交通大学医学院附属上海儿童医学中心 |
一种检测染色体重复片段断裂位点和定位信息的方法
|
WO2020069029A1
(en)
|
2018-09-26 |
2020-04-02 |
Emendobio Inc. |
Novel crispr nucleases
|
JP2022505381A
(ja)
|
2018-10-18 |
2022-01-14 |
インテリア セラピューティクス,インコーポレーテッド |
アルファ1アンチトリプシン欠乏症を治療するための組成物及び方法
|
CN113260701A
(zh)
|
2018-10-18 |
2021-08-13 |
英特利亚治疗股份有限公司 |
用于表达因子ix的组合物和方法
|
KR20210102882A
(ko)
|
2018-10-18 |
2021-08-20 |
인텔리아 테라퓨틱스, 인크. |
핵산 구조체 및 사용 방법
|
KR20210102883A
(ko)
|
2018-10-18 |
2021-08-20 |
인텔리아 테라퓨틱스, 인크. |
알부민 좌위로부터 트랜스진을 발현하기 위한 조성물 및 방법
|
EP3673920A1
(en)
|
2018-12-28 |
2020-07-01 |
Universität Wien |
Polyphenol-peptide conjugates for nuclear-targeted delivery
|
WO2020146805A1
(en)
|
2019-01-11 |
2020-07-16 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
WO2020163379A1
(en)
|
2019-02-05 |
2020-08-13 |
Emendobio Inc. |
Crispr compositions and methods for promoting gene editing of ribosomal protein s19 (rps19) gene
|
EP3826664A4
(en)
|
2019-02-06 |
2022-10-26 |
Sangamo Therapeutics, Inc. |
METHOD FOR THE TREATMENT OF TYPE I MUCOPOLYSACCHARIDOSES
|
WO2020163307A1
(en)
|
2019-02-06 |
2020-08-13 |
Emendobio Inc. |
New engineered high fidelity cas9
|
WO2020223571A1
(en)
|
2019-05-01 |
2020-11-05 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
|
KR20220016475A
(ko)
|
2019-05-01 |
2022-02-09 |
주노 쎄러퓨티크스 인코퍼레이티드 |
변형된 tgfbr2 유전자 좌에서 재조합 수용체를 발현하는 세포, 관련 폴리뉴클레오티드 및 방법
|
BR112021023594A2
(pt)
|
2019-05-28 |
2022-02-08 |
Selecta Biosciences Inc |
Métodos e composições para resposta imune de vetor de transferência antiviral atenuada
|
US20210079387A1
(en)
*
|
2019-08-27 |
2021-03-18 |
The Jackson Laboratory |
Cleavage-resistant donor nucleic acids and methods of use
|
WO2021080962A1
(en)
*
|
2019-10-21 |
2021-04-29 |
Rowan University |
Methods of precise genome editing by in situ cut and paste (icap)
|
WO2021231661A2
(en)
|
2020-05-13 |
2021-11-18 |
Juno Therapeutics, Inc. |
Process for producing donor-batched cells expressing a recombinant receptor
|
JP2023531531A
(ja)
|
2020-06-26 |
2023-07-24 |
ジュノ セラピューティクス ゲーエムベーハー |
組換え受容体を条件付きで発現する操作されたt細胞、関連ポリヌクレオチド、および方法
|
EP4182297A1
(en)
|
2020-07-16 |
2023-05-24 |
Acuitas Therapeutics, Inc. |
Cationic lipids for use in lipid nanoparticles
|
CN116802203A
(zh)
|
2020-11-04 |
2023-09-22 |
朱诺治疗学股份有限公司 |
从经修饰的恒定cd3免疫球蛋白超家族链基因座表达嵌合受体的细胞、相关多核苷酸和方法
|
CA3200855A1
(en)
|
2020-11-16 |
2022-05-19 |
Pig Improvement Company Uk Limited |
Influenza a-resistant animals having edited anp32 genes
|
CA3208944A1
(en)
|
2021-03-22 |
2022-09-29 |
Edith NALBANDIAN |
Method to assess potency of viral vector particles
|
CN118019546A
(zh)
|
2021-03-23 |
2024-05-10 |
艾欧凡斯生物治疗公司 |
肿瘤浸润淋巴细胞的cish基因编辑及其在免疫疗法中的用途
|
KR20240051112A
(ko)
|
2021-07-01 |
2024-04-19 |
인답타 세라뷰틱스 인코포레이티드 |
조작된 자연 살해(nk) 세포 및 관련 방법
|
US20230141563A1
(en)
|
2021-10-12 |
2023-05-11 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuating anti-viral transfer vector igm responses
|
CA3232470A1
(en)
|
2021-10-27 |
2023-05-04 |
Leah SABIN |
Compositions and methods for expressing factor ix for hemophilia b therapy
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
WO2023105244A1
(en)
|
2021-12-10 |
2023-06-15 |
Pig Improvement Company Uk Limited |
Editing tmprss2/4 for disease resistance in livestock
|
AR128001A1
(es)
|
2021-12-17 |
2024-03-20 |
Denali Therapeutics Inc |
Anticuerpos anti-pilra, usos de estos y métodos y reactivos relacionados
|
WO2023150623A2
(en)
|
2022-02-02 |
2023-08-10 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease
|
US20230357437A1
(en)
|
2022-03-09 |
2023-11-09 |
Selecta Biosciences, Inc. |
Immunosuppressants in combination with anti-igm agents and related dosing
|
WO2023212677A2
(en)
|
2022-04-29 |
2023-11-02 |
Regeneron Pharmaceuticals, Inc. |
Identification of tissue-specific extragenic safe harbors for gene therapy approaches
|
WO2024007020A1
(en)
|
2022-06-30 |
2024-01-04 |
Indapta Therapeutics, Inc. |
Combination of engineered natural killer (nk) cells and antibody therapy and related methods
|
WO2024013514A2
(en)
|
2022-07-15 |
2024-01-18 |
Pig Improvement Company Uk Limited |
Gene edited livestock animals having coronavirus resistance
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|